Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|VB-111||Ofranergene Obadenovec||VB111||Ofranergene Obadenovec (VB-111) is an engineered adenovirus that expresses Fas-c specifically within endothelial cells, resulting in endothelial cell death and decreased tumor blood supply, and potentially leading to tumor cell death (PMID: 22701765)|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung cancer||not applicable||VB-111||Preclinical||Actionable||In a preclinical study, VB-111 treatment resulted in increased tumor lymphocyte infiltration and reduced tumor burden in animal models of lung cancer (AACR Annual Meeting 2019, Abstract 4979).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02511405||Phase III||Bevacizumab VB-111||A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)||Completed|